The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...
Hosted on MSN1mon
Leerink raises 89bio stock target to $37 on NASH study optimismThe results demonstrated a statistically significant fibrosis benefit, which Smith regards as transformational for the field and supportive of ETNB's FGF21 analog, pegozafermin, in NASH.
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
This article reviews evidence that causally links hormonal disorders with hepatobiliary disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by ...
The company has recently completed enrollment for its Phase 3 ENTRUST study focused on pegozafermin for severe ... for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results